Format
Sort by

Send to:

Choose Destination

Results: 2

1.

Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.

Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB; Drug-Induced Liver Injury Network; DILIGEN; EUDRAGENE; Spanish DILI Registry; International Serious Adverse Events Consortium.

Pharmacogenet Genomics. 2012 Nov;22(11):784-95. doi: 10.1097/FPC.0b013e3283589a76.

2.

A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.

Newman WG, Payne K, Tricker K, Roberts SA, Fargher E, Pushpakom S, Alder JE, Sidgwick GP, Payne D, Elliott RA, Heise M, Elles R, Ramsden SC, Andrews J, Houston JB, Qasim F, Shaffer J, Griffiths CE, Ray DW, Bruce I, Ollier WE; TARGET study recruitment team.

Pharmacogenomics. 2011 Jun;12(6):815-26. doi: 10.2217/pgs.11.32. Epub 2011 May 3.

PMID:
21692613

Supplemental Content

Loading ...
Write to the Help Desk